Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH CVE:GSH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.53+6.5%$19.90$16.65▼$31.26$808.22M0.91620,493 shs660,867 shsGSHGolden Share ResourcesC$0.05-10.0%C$0.04C$0.04▼C$0.17C$2.17M1.3227,455 shs13,000 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+6.55%-2.15%+6.08%-0.20%-20.87%GSHGolden Share Resources0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$19.53+6.5%$19.90$16.65▼$31.26$808.22M0.91620,493 shs660,867 shsGSHGolden Share ResourcesC$0.05-10.0%C$0.04C$0.04▼C$0.17C$2.17M1.3227,455 shs13,000 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+6.55%-2.15%+6.08%-0.20%-20.87%GSHGolden Share Resources0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 1.88Reduce$24.0022.89% UpsideGSHGolden Share Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OPG, AMPH, GSH, and ETP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$23.00 ➝ $20.005/14/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$30.00 ➝ $19.005/11/2026AMPHAmphastar Pharmaceuticals Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$25.00 ➝ $21.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/8/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $23.00(Data available from 6/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.20$4.53 per share4.31$17.17 per share1.14GSHGolden Share ResourcesC$10K216.86C$0.01 per share4.50N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$1.6611.776.673.6011.00%15.12%7.14%8/6/2026 (Estimated)GSHGolden Share ResourcesN/A-C$0.01N/AN/AN/A-106.97%-490.27%-18.89%N/ALatest OPG, AMPH, GSH, and ETP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026AMPHAmphastar Pharmaceuticals$0.70$0.42-$0.28$0.14$173.46 million$171.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AGSHGolden Share ResourcesC$0.511,133.33%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.793.852.82GSHGolden Share Resources170.240.890.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%GSHGolden Share ResourcesN/AInsider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%GSHGolden Share Resources19.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.09 million31.04 millionOptionableGSHGolden Share Resources42,58348.19 millionN/ANot OptionableOPG, AMPH, GSH, and ETP HeadlinesRecent News About These CompaniesNippon Steel Completes $14.9B U.S. Steel Deal with Golden Share OversightJune 19, 2025 | msn.comLipari Mining Ltd. (formerly, Golden Share Resources Corporation) Receives Final Approval to ...March 28, 2025 | goldseiten.deLipari Mining Ltd. (Formerly, Golden Share Resources Corporation) Announces Share Consolidation and Name ChangeFebruary 4, 2025 | finance.yahoo.comGolden Share Announced Property Purchase Agreement with Delta Resources Limited and Extension of Share Agreement with Lipari DiamondNovember 21, 2024 | finance.yahoo.comGreat Atlantic Resources (TSXV:GR) Intersects Visible Gold in Latest Drilling at Golden Promise Property, NewfoundlandOctober 31, 2024 | miningfeeds.comMGolden opportunity to find out about Golden Share home ownership schemeOctober 30, 2024 | edinburghnews.scotsman.comEGolden Goliath Sells Mexican Exploration AssetsOctober 28, 2024 | markets.businessinsider.comGolden Mile Resources Boosts Pearl Copper Project FundingOctober 22, 2024 | markets.businessinsider.comGolden Mile Resources Announces New Securities IssueOctober 22, 2024 | markets.businessinsider.comGolden Mile Resources Plans Major Securities IssueOctober 22, 2024 | markets.businessinsider.comHesai's Market Share: A Golden Investment OpportunityOctober 7, 2024 | seekingalpha.comGolden Triangle Ventures Secures Full Operational Control of its Logistics Assets and Initiates Cash FlowOctober 4, 2024 | markets.businessinsider.comCanada announces $151 million for polio eradication, after outbreak in Gaza StripSeptember 22, 2024 | ctvnews.caCExploding electronic devices kill 20, wound 450 in second day of explosions in LebanonSeptember 19, 2024 | ctvnews.caCGolden Crest Education & Service share priceSeptember 14, 2024 | livemint.comDelta Resources Limited (DTARF)September 14, 2024 | finance.yahoo.comHi-View’s Golden Stranger Property Returns Gold and Silver Sample Results and Anomalous Gold ZonesAugust 22, 2024 | markets.businessinsider.comGolden Chick Honors Franchisee SXThree with Milestone AwardAugust 3, 2024 | qsrmagazine.comQGolden Energy Group Inks $600 Million Private Loan for Coal DealJuly 22, 2024 | bloomberg.comGolden Goliath Share ChatMay 28, 2024 | lse.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPG, AMPH, GSH, and ETP Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$19.53 +1.20 (+6.55%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$19.52 -0.01 (-0.03%) As of 06/23/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Golden Share Resources CVE:GSHC$0.04 -0.01 (-10.00%) As of 02/2/2023Golden Share Resources Corporation engages in the exploration and evaluation of mineral resources in Canada. It primarily explores for gold, base metals, copper, nickel, and diamond deposits. The company holds 100% interests in the Ogoki project comprising ten non-contiguous claim blocks with 30 MLAS mining claims located in the James Bay Lowlands of Ontario; the Kagiami project comprising five small non-contiguous blocks that include 24 MLAS cell claims located in the James Bay Lowlands of Ontario; the Petawanga project comprising one contiguous claim block totalling 4 MLAS cell claims located near north of Lake Nipigon, Northern Ontario; and the Band-Ore project comprising 109 MLAS cell claims, 16 patented claims and 1 Mining lease claim located near west of Thunder Bay, Ontario. It also holds 40% interest in the Pense project comprising 39 claims located in Pense township, Ontario. The company was formerly known as Golden Share Mining Corporation and changed its name to Golden Share Resources Corporation in June 2017. Golden Share Resources Corporation is based in Markham, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
